肌萎缩侧索硬化
肌萎缩侧索硬化是一种致死性中枢神经系统神经退行性疾病,尽管研究深入,其从诊断到预后的管理仍不理想。本文综述表型异质性、全局中枢神经系统功能障碍、遗传架构及新诊断标准对临床识别与诊断的促进作用,并讨论生物标志物、可干预风险、预测模型及基于机制的治疗试验管线对预后格局的改变,指出肌萎缩侧索硬化作为复杂综合征的理念已在临床产生实际影响。
要点
- 肌萎缩侧索硬化的管理从诊断到预后仍不理想,尽管研究密集。
- 表型异质性、全局中枢神经系统功能障碍、遗传架构及新诊断标准有助于明确临床谱系和促进诊断。
- 病理生理学见解、生物标志物、可干预风险、预测模型及基于机制的治疗试验管线正在改变预后格局。
核心结论
- 肌萎缩侧索硬化是一种致死性中枢神经系统神经退行性疾病,当前从诊断到预后的管理仍不理想。
- 尽管多数近期进展尚未转化为患者获益,但将肌萎缩侧索硬化视为复杂综合征的理念已在临床产生实际影响。
研究设计与样本
- 本文为综述(Seminar),面向普通神经科医生概述肌萎缩侧索硬化的管理现状及未来前景。
主要发现
- 对表型异质性、全局中枢神经系统功能障碍、遗传架构及新诊断标准的认识正在明确临床谱系并促进诊断。
- 对病理生理学的见解、疾病生物标志物和可干预风险的识别,以及新预测模型、量表和评分系统及基于机制的治疗临床试验管线,正在改变预后格局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Amyotrophic lateral sclerosis is a fatal CNS neurodegenerative disease. Despite intensive research, current management of amyotrophic lateral sclerosis remains suboptimal from diagnosis to prognosis. Recognition of the phenotypic heterogeneity of amyotrophic lateral sclerosis, global CNS dysfunction, genetic architecture, and development of novel diagnostic criteria is clarifying the spectrum of clinical presentation and facilitating diagnosis. Insights into the pathophysiology of amyotrophic lateral sclerosis, identification of disease biomarkers and modifiable risks, along with new predictive models, scales, and scoring systems, and a clinical trial pipeline of mechanism-based therapies, are changing the prognostic landscape. Although most recent advances have yet to translate into patient benefit, the idea of amyotrophic lateral sclerosis as a complex syndrome is already having tangible effects in the clinic. This Seminar will outline these insights and discuss the status of the management of amyotrophic lateral sclerosis for the general neurologist, along with future prospects that could improve care and outcomes for patients with amyotrophic lateral sclerosis.
引用
- Feldman EL, Goutman SA, Petri S, et al. Amyotrophic lateral sclerosis. Lancet. 2022. PMID: 36116464. doi:10.1016/S0140-6736(22)01272-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。